Philips' Ingenuity TF PET/MR has obtained the CE mark, making the whole body PET/MR system commercially available in Europe.
The Ingenuity TF PET/MR integrates PET's molecular imaging capabilities with MRI's high soft tissue contrast, where the scanners, configured three meters apart, can capture independent or integrated PET/MR images. According to Amsterdam-based Royal Philips Electronics, the system has been installed in three hospitals, including the University Hospital of Geneva, Mount Sinai School of Medicine in Manhattan, N.Y., and the Institute of Radiopharmacy, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), in Dresden, Germany.
In addition to its use for heart disease screening and early tumor detection, Philips indicated that the TF PET/MR could track whether a drug reaches a tumor or plaque and its treatment efficacy. The company is marketing the scanner as "the first new imaging modality in 10 years," aiming the system's ostensible early detection capabilities at an increasing trend towards personalized medicine.